NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Diakonos Oncology

Diakonos Oncology

Private
Houston, TexasHealthcare & Life Scienceshttps://www.diakonosoncology.com/

Last Round

Grant

Nov 19, 2025

Total Funding Raised

$38.56M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Diakonos Oncology is a biotechnology company that develops a clinical-stage immunotherapy platform intended to focus on treating aggressive cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

dendritic cell vaccinecancer immunotherapysolid tumor treatmentcell therapypancreatic cancerglioblastomacancer vaccineclinical-stage biotechpersonalized medicinetumor microenvironmentbiotech startuponcology researchclinical trialscancer drug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Diakonos Oncology Comps

Public and private peers based on sector, stage, and business model.

Diakonos Oncology comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Diakonos Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 19, 2025
SAFEMay 30, 2025
SeedAug 26, 2024

Key People

Founding team and executive leadership

Mike Wicks

Chief Executive Officer

Executive Team

Jay Hartenbach

President, Chief Operating Officer

Executive Team

Donna Rill

Chief Technology Officer

Executive Team

Diakonos Oncology Investors

Notable investors and investment history

Diakonos Oncology investors
InvestorRounds
Buttonwood Group AdvisorsSAFE
Cancer Prevention and Research Institute of TexasGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 129% MoM, reaching 3K.

  • Mar 18, 2026

    Will attend ANN 2026 to showcase clinical data for DOC1021.

Diakonos Oncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Diakonos Oncology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Diakonos Oncology's valuation, stock price, and market status.

Firmographic Details

HeadquartersHouston, Texas
Employee Range23
Year Founded2022
Last FundingNov 19, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.